◆ Key Takeaways
- NIH SBIR Phase I pays up to $316,219 for 6 months; Phase II awards up to $2,099,398 for 24 months — funding is non-dilutive (no equity exchange), which makes it one of the highest-value early-stage funding sources for biohealth startups.
- The April 5, 2026 deadline is the standard new Phase I window — miss it and the next opportunity is September 5 — a six-month gap; resubmissions (A1) for prior unfunded applications are due June 5.
- The Principal Investigator must be primarily employed at the small business at the time of award — not at a university; STTR relaxes this but requires a formal subcontract with a nonprofit research institution performing at least 30% of the work.
- The commercialization plan is a scored evaluation criterion, not an appendix — it must describe a credible path to market: target customers, regulatory pathway (IDE, 510(k), IND, etc.), and revenue model; generic commercialization sections are among the top reasons SBIR applications score poorly.
- Fast-Track applications combine Phase I and Phase II into a single submission — this reduces the total timeline by 9–12 months but sets a higher bar for preliminary data and commercial readiness at the time of submission.
Deadline Alert
The NIH SBIR/STTR standard due date for new Phase I applications is April 5, 2026. Resubmission deadline was March 5. The next new application window opens September 5, 2026. If you miss April 5, your next opportunity is six months away.
Summary
NIH SBIR (Small Business Innovation Research) and STTR (Small Business Technology Transfer) programs collectively award approximately $1 billion per year to small businesses developing biomedical, health technology, and life science innovations. Phase I awards fund proof-of-concept work up to $316,219 over six months. The April 5, 2026 standard due date applies to new Phase I applications across all NIH Institutes and Centers — covering therapeutics, medical devices, diagnostics, health IT, behavioral health, and basic research with commercial potential.
What's Funded
NIH SBIR Phase I awards provide up to $316,219 over six months to fund proof-of-concept work demonstrating scientific, technical, and commercial feasibility. Phase II awards — applied for based on demonstrated Phase I success — provide up to $2,099,398 over 24 months for full R&D and prototype development. For teams that want to compress the timeline, the Fast-Track option allows simultaneous submission of Phase I and Phase II as a single application, skipping the gap between phases at the cost of a higher preliminary data threshold.
Eligible research areas are broad by design — therapeutics, diagnostics, medical devices, digital health tools, behavioral interventions, and basic science with a credible commercialization path. The common thread is that research must have health relevance and commercial potential; purely academic science without a product pathway doesn't fit the program. Critically, NIH SBIR funding is non-dilutive — the agency takes no equity in your company, which makes it one of the highest-value early-stage funding sources available to biohealth startups.
Eligibility Requirements
SBIR applicants must be for-profit U.S. small businesses with 500 or fewer employees, at least 51% owned and controlled by U.S. citizens or permanent resident aliens. The Principal Investigator must be primarily employed at the small business at the time of award — this is a hard requirement that cannot be met by a PI who is primarily employed at a university with a nominal consulting relationship to the company. STTR is structured differently: it requires a formal written agreement with a nonprofit research institution (university, federal lab, or nonprofit research organization) that performs at least 30% of the funded work, which makes it the right vehicle for PI-university partnerships where the academic institution is doing substantial R&D.
Registration requirements must be in place before you submit: active SAM.gov registration, a Grants.gov account registered with your UEI number, and a NIH eRA Commons account with an Authorized Organization Representative designated. If any of these are missing or expired, allow 3–5 business days minimum for setup — don't leave this for the week of the deadline.
How to Apply — Step by Step
Begin by identifying which NIH Institute or Center (IC) fits your technology area. Use the matchmaker tool at sbir.nih.gov to find the most relevant IC, then contact the program officer there for informal pre-submission guidance — this is expected and actively encouraged. Different ICs have different priorities, paylines, and study section cultures, and a 15-minute call with the right program officer can significantly sharpen your application. Most Phase I applications use the parent FOA (PA-24-185 for SBIR, PA-24-186 for STTR), but check whether your IC has published a specialized FOA with additional requirements for your technology area.
The core application package for Phase I includes: a 1-page Specific Aims, a 6-page Research Strategy covering Significance, Innovation, and Approach, Bibliography, Budget with detailed line-item justification, biosketches for all key personnel, a commercialization plan, and a Facilities and Resources description. Submit to Grants.gov at least 2 full business days before April 5 — NIH does not grant extensions for last-minute technical issues. After submission, monitor your application in eRA Commons for acceptance confirmation, study section assignment, and review scores, which are typically released approximately 3 months after the due date.
Key Dates for NIH SBIR/STTR 2026
◆ Action Checklist
- Contact your NIH IC Program Officer now — send a 1-paragraph technology summary and ask whether it fits their portfolio and which FOA to use; this call is expected and often shapes a stronger application.
- Verify all registrations are current — SAM.gov active, Grants.gov registered with your UEI, eRA Commons account in place with an AOR designated; allow 3–5 days if anything needs setup.
- Write the Specific Aims page first — clearly state the problem, your innovative approach, and expected outcomes in one page; reviewers and program officers read this first, and it determines whether the rest of the application gets serious attention.
- Build a detailed commercialization plan — name the target customer segment, the regulatory pathway (510(k), PMA, IND, De Novo, etc.), and your revenue model; reviewers score this as a primary criterion, not a formality.
- Include preliminary data even if early-stage — bench data, pilot study results, or in vitro proof of concept dramatically strengthens feasibility scoring; applications with no data at all face an uphill review.
- Submit to Grants.gov by April 2 at the latest — NIH does not grant deadline extensions for technical submission problems; eRA Commons confirmation (not just Grants.gov acknowledgment) is required to confirm receipt.
Frequently Asked Questions
When are NIH SBIR/STTR deadlines?
Standard due dates are January 5, April 5, and September 5 each year. AIDS-related applications follow the separate AIDS cycle. Submissions go through ASSIST or Grants.gov with eRA Commons registration, which small businesses should complete at least a month before the deadline.
How much can an NIH SBIR award provide?
Phase I budgets are normally capped around $314,000 total and Phase II around $2.1 million (caps adjust periodically, and some topics have approved waivers allowing more). Fast-Track applications combine both phases in one submission for projects with strong commercial plans.
Does my company need a scientist as PI?
The principal investigator must be primarily employed (more than 50 percent) by the small business at award time for SBIR — they do not need a PhD, but they need credentials appropriate to the science. STTR allows the PI to remain at the partner research institution.
What makes NIH SBIR different from other agencies?
NIH SBIR is grant-based and investigator-initiated — you propose your own topic within an institute's mission rather than responding to prescribed topics like DoD. NIH also offers a technical assistance program, commercialization support, and the application is peer-reviewed like other NIH grants.